zolbetuximab
Showing 1 - 7 of 7
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric
Available
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
- +3 more
- zolbetuximab
-
Morristown, New JerseyAMG Hematology/Oncology
Sep 15, 2023
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Trial in Guangzhou (zolbetuximab)
Completed
- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- zolbetuximab
-
Guangzhou, ChinaSite CN86001
Jan 11, 2022
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric
Active, not recruiting
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- +3 more
- zolbetuximab
- +3 more
-
Los Angeles, California
- +164 more
Jan 16, 2023
Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer Trial in Kashiwa (Zolbetuximab)
Completed
- Gastric Cancer
- Gastro-esophageal Junction (GEJ) Cancer
- Zolbetuximab
-
Kashiwa, Chiba, JapanSite JP00001
Mar 3, 2021
Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma Trial in Worldwide (zolbetuximab,
Recruiting
- Pancreatic Cancer
- +2 more
- zolbetuximab
- +2 more
-
Goodyear, Arizona
- +131 more
Jan 30, 2023
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric
Active, not recruiting
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- +3 more
- zolbetuximab
- +4 more
-
Phoenix, Arizona
- +219 more
Aug 16, 2022
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus,
Completed
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- +2 more
- epirubicin
- +3 more
-
Plovdiv, Bulgaria
- +47 more
Jan 14, 2020